Yam Code

New Paste Browse

https://www.selleckchem.com/products/otub2-in-1.html Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease. We tested the metronomic treatment principle with vinorelbine in a randomized phase 2 setting combined with standard capecitabine treatment in the XeNa trial with Clinical Trials.gov identifier number NCT0141771. 120 patients with disseminated HER2 non-amplified breast cancer were included. Randomization was between Arm A vinorelbine 60 mg/m day 1 + day 8 in the first cycle followed by 80 mg/m day 1 + day 8 in the following cycles or Arm B vinorelbine 50 mg three times a week. Capecitabine 1000 mg/m twice a day for days 1-14 was administered in both arms. The treatment was generally well-tolerated. The response rate (RR) was 24% (arm A) 29% (arm B) (  = .67). The clinical benefit rate (CBR) 46.8% (arm A) 51.7% (arm B) (  = .72). We found a median progression-free survival (PFS) of 7.1 months (95% confidence interval [CI] 3.9-10.3) in arm A and 6.3 months (95% CI 4.1-8.5) in arm B (  = .25) whereas median overall survival (OS) was 23.3 months (95% CI 20.2-26.4) in arm A and 22.3 months (95% CI 14.3-30.3) in arm B (  = .76). We confirmed that the combination of vinorelbine and capecitabine was well tolerated. Metronomic treatment can be used with acceptable adverse events (AEs), but we did not find significant difference in the effect compared to the standard treatment. We confirmed that the combination of vinorelbine and capecitabine was well tolerated. Metronomic treatment can be used with acceptable adverse events (AEs), but we did not find significant difference in the effect compared to the standard treatment.Purpose Computerised rehabilitation programs can be used to address cognitive deficits typically caused by multiple sclerosis (MS). However, there are still doubts on their effectiveness, due to mixed results obtained in clinical trials. The objec

Paste Settings

Paste Title : [Optional]

Paste Folder : [Optional]

Syntax Highlighting : [Optional]

Paste Expiration : [Optional]

Paste Status : [Optional]

Password : [Optional]

Description: [Optional]

Tags: [Optional]

Encrypt Paste (?)

You are currently not logged in, this means you can not edit or delete anything you paste. Sign Up or Login

Paste Settings

Site Languages